A practical reference on freeze-thaw cycling: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-03-22 and is reviewed periodically as new material appears.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.
Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.
Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.
Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.
Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.
| Property | Value | Notes |
|---|---|---|
| Class | Synthetic peptide | 28 residues; not a small-molecule compound |
| Molecular mass | About 3,106 Da | Monoisotopic mass of the unmodified chain |
| N-terminal group | Acetylated serine | Present in both native and synthetic forms |
| Secondary structure | Disulfide-constrained loop | One bridge between two cysteine residues |
| Typical source | Solid-phase synthesis | Early isolates came from bovine thymus extracts |
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.
Biologically, the peptide is studied mainly in the context of immune cell development and regulation. It is produced in the thymus and in several other tissues, and it appears to influence the maturation and activity of T cells and other immune populations. Laboratory work describes effects on cytokine production, on the balance between T cell subsets, and on the function of dendritic cells. Much of this evidence comes from cell culture and animal models, so the extent to which the same pathways operate in humans remains an open question.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.
Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated or chemically modified byproducts. Mass spectrometry confirms the expected molecular mass and can indicate acetylation state or sequence errors. Amino acid analysis and peptide mapping supply complementary sequence-level information, while endotoxin testing is relevant for preparations intended for cell or animal work. Purity figures reported by suppliers refer to the method used and are not directly comparable across laboratories unless conditions are stated.
Lyophilized material is typically treated as a hygroscopic solid that should be brought to room temperature before the container is opened, which limits condensation on the powder. Reconstitution is commonly done with sterile water or a buffered diluent, and gentle mixing is preferred over vigorous agitation to reduce foaming and surface adsorption. Because peptides can bind to plastic and glass, diluents containing a small amount of carrier protein are sometimes used in laboratory work. Working solutions are generally aliquoted and prepared fresh rather than subjected to repeated freezing and thawing.
Stability depends on temperature, pH, and the number of freeze-thaw events the sample has experienced. Freeze-dried material is commonly held at -20 °C or colder, while reconstituted liquid is kept cold and used within a short window. Extreme pH and prolonged light exposure can promote deamidation, oxidation, or aggregation, particularly at asparagine and methionine positions. Adsorption to container walls can lower the measured concentration of a dilute solution even when the peptide molecules themselves remain intact.
Thymosin beta-4 is a separate 43-residue peptide that binds actin and participates in cell migration; it shares no sequence similarity with thymosin alpha-1 despite the common family name. Other preparative materials, such as thymosin fraction 5 and thymopoietin, contain distinct mixtures or peptides. The shared thymosin label reflects the tissue of origin used in early purification, not a common structural core. Treating these molecules as interchangeable is a frequent source of confusion in laboratory reports and in popular summaries alike.
Thymosin alpha-1 is a synthetic peptide of 28 amino acid residues that corresponds to a naturally occurring fragment first isolated from thymus tissue. Its chain is acetylated at the amino terminus, a modification that shields the peptide from rapid cleavage by aminopeptidases. The molecule carries a net negative charge at physiological pH and dissolves freely in water. Researchers classify it as an immune-modulating agent rather than a classical hormone, because it acts on several cell types of both the innate and the adaptive immune system.
The peptide was identified during work in the 1970s on thymosin fraction 5, a partially purified extract of calf thymus. Investigators separated that mixture and characterized individual components, one of which they named thymosin alpha-1. The same compound later received the international nonproprietary name thymalfasin. Commercial material is produced by solid-phase peptide synthesis rather than by extraction, so synthetic and natural forms share an identical sequence. Naming conventions vary across the literature, and readers should distinguish the alpha-1 peptide from other thymosins that have unrelated sequences and functions.
=== Diet control === A diet with carefully controlled levels of the amino acids leucine, isoleucine, and valine must be maintained at all times to reduce toxic metabolites to prevent neurological damage. Since these three amino acids occur in all-natural protein, and most natural foods contain some protein, any food intake must be closely monitored, and day-to-day protein intake calculated on a cumulative basis, to ensure individual tolerance levels are not exceeded at any time. As the MSUD diet is so protein-restricted, and adequate protein is a requirement for all humans, a tailored metabolic formula containing all the other essential amino acids, as well as any vitamins, minerals, omega-3 fatty acids and trace elements (which may be lacking due to the limited range of permissible foods), are an essential aspect of MSUD management. These complement the MSUD patient's natural food intake to meet normal nutritional requirements without causing harm. If adequate calories cannot be obtained from natural food without exceeding protein tolerance, specialized low protein products such as starch-based baking mixtures, imitation rice and pasta may be prescribed, often alongside a protein-free carbohydrate powder added to food and/or drink, and increased at times of metabolic stress. MSUD patients with thiamine-responsive MSUD can have a higher protein intake diet with the administration of high doses of thiamine, a cofactor of the enzyme that causes the condition.
Veins vary in size from the smallest post-capillary venules, and more muscular venules, to small veins, medium veins, and large veins. The thickness of the walls of the veins varies as to their location – in the legs the vein walls are much thicker than those in the arms. In the circulatory system, blood first enters the venous system from capillary beds where arterial blood changes to venous blood. Large arteries such as the thoracic aorta, subclavian, femoral and popliteal arteries lie close to a single vein that drains the same region. Other arteries are often accompanied by a pair of veins held in a connective tissue sheath. The accompanying veins are known as venae comitantes, or satellite veins, and they run on either side of the artery. When an associated nerve is also enclosed, the sheath is known as a neurovascular bundle. This close proximity of the artery to the veins helps in venous return due to the pulsations in the artery. It also allows for the promotion of heat transfer from the larger arteries to the veins in a counterflow exchange that helps to preserve normal body heat.
=== Formulations === Available dosage forms include liquids, syrups, drops, elixirs, effervescent tablets, and powders for mixing with water, capsules, tablets including extended-release formulations, suppositories, compounding powder, and injections.
== Sierra Leone == Amadu Wurie - Educationist and politician, First Minister of Education and later Minister of Interior of Sierra Leone Sir Banja Tejan-Sie - Politician and lawyer. former vice president under SLPP (1953–1956), former chief justice and Governor-General of Sierra Leone Mohamed Juldeh Jalloh – Current vice president, Republic of Sierra Leone Abass Bundu – Current Speaker of Parliament Sierra Leone, former minister of foreign affairs, former Executive Secretary of the Economic Community of West African States Ibrahim Bundu - former majority leader of the Sierra Leone Parliament, Sierra Leone Abdulai Hamid Charm - former chief justice, Sierra Leone Umu Hawa Tejan-Jalloh – former chief justice, Diplomat, Sierra Leone Miatta Maria Samba - Sierra Leonian jurist and current judge at the International Criminal Court (ICC). Sulaiman Tejan-Jalloh – politician and Diplomat, former Minister of Transport and Communications and former ambassador to US, Sierra Leone Neneh Cherry (birth name Neneh Mariann Karlsson) – Singer-songwriter, rapper, occasional DJ and broadcaster, Sweden Titiyo (birth name Titiyo Yambalu Felicia Jah) – singer and songwriter, Sweden Alpha Timbo – Politician, educationist, lecturer and trade unionist. Minister of Primary and Secondary Education, former Minister of Labor and Industrialization, Sierra Leone Chernor Bah - Minister of Information and Civic Education Chernor Maju Bah – lawyer and politician.
Sources: en.wikipedia.org
=== World Health Organization === The World Health Organization has declared that finding where SARS-CoV-2 came from is a priority and that it is "essential for understanding how the pandemic started." In May 2020, the World Health Assembly, which governs the World Health Organization (WHO), passed a motion calling for a "comprehensive, independent and impartial" study into the COVID-19 pandemic. A record 137 countries, including China, co-sponsored the motion, giving overwhelming international endorsement to the study. In mid 2020, the World Health Organization (WHO) began negotiations with the government of China on conducting an official study into the origins of COVID-19. In November 2020, the WHO published a two-phase study plan. The purpose of the first phase was to better understand how the virus "might have started circulating in Wuhan", and a second phase involves longer-term studies based on the findings of the first phase. WHO director-general Tedros Adhanom said "We need to know the origin of this virus because it can help us to prevent future outbreaks," adding, "There is nothing to hide. We want to know the origin, and that's it." He also urged countries not to politicise the origin tracing process, saying that would only create barriers to learning the truth. In 2021, the World Health Assembly (on behalf of the WHO) commissioned a study conducted jointly between WHO experts and Chinese scientists. Echoing the assessment of most virologists, the study concluded that the virus most likely had a zoonotic origin in bats, possibly via an intermediate host.
DiCaprio turned down the role of Anakin Skywalker in Star Wars: Episode II – Attack of the Clones (2002), feeling unprepared to "take that dive" at the time. His first film that year was the biopic Catch Me If You Can, based on the life of Frank Abagnale Jr., who before his 19th birthday committed check fraud to make millions in the 1960s. Directed by Steven Spielberg, the film was shot across 147 different locations in 52 days, making it "the most adventurous, super-charged movie-making" DiCaprio had experienced yet. The film received critical acclaim and grossed $355 million against a budget of $52 million, becoming his second highest-grossing release after Titanic. Roger Ebert praised his departure from dark and troubled characters, and two Entertainment Weekly critics in 2018 called it DiCaprio's best role, labeling him "delightfully persuasive, deceptive, flirtatious, and sometimes tragic—and we dare you to find a better role, if you can". DiCaprio received his third Golden Globe nomination for his performance in the film. Also in 2002, DiCaprio starred in Martin Scorsese's Gangs of New York, a historical drama set in the mid-19th century in the Five Points district of New York City. Scorsese initially struggled selling his idea of realizing the film until DiCaprio became interested in starring in the film, and thus Miramax Films got involved with financing the project. Nonetheless, production on the film was plagued by overshooting of budgets and producer-director disagreements, resulting in an eight-month shoot.
=== Comorbid conditions === In one case, a patient was diagnosed with both Morvan's syndrome and pulmonary hyalinizing granulomas (PHG). PHG are rare fibrosing lesions of the lung, which have central whorled deposits of lamellar collagen. How these two diseases relate to one another is still unclear. Thymoma, prostate adenoma, and in situ carcinoma of the sigmoid colon have also been found in patients with Morvan's Syndrome.
== G == Gabriel ethylenimine method Gabriel synthesis Gabriel–Colman rearrangement, Gabriel isoquinoline synthesis Gallagher–Hollander degradation Gassman indole synthesis Gastaldi synthesis Gattermann aldehyde synthesis Gattermann Koch reaction Gattermann reaction Geminal halide hydrolysis Gewald reaction Gibbs phthalic anhydride process Gilman reagent Glaser coupling Glycol cleavage Goldberg reaction Gomberg–Bachmann reaction Gomberg–Bachmann–Hey reaction Gomberg radical reaction Gould–Jacobs reaction Graebe–Ullmann synthesis Grignard degradation Griesbaum coozonolysis Grignard reaction Grob fragmentation Grubbs' catalyst in Olefin metathesis Grundmann aldehyde synthesis Gryszkiewicz–Trochimowski and McCombie method Guareschi–Thorpe condensation Guerbet reaction Gutknecht pyrazine synthesis
=== TNXB (functional gene) === The TNXB gene localizes to the major histocompatibility complex (MHC class III) region on chromosome 6. The structure of this gene is unusual in that it overlaps the CREBL1 and CYP21A2 genes at its 5' and 3' ends, respectively.
Sources: en.wikipedia.org
=== Environmental effects === Fluoxetine has been detected in aquatic ecosystems, especially in North America. There is a growing body of research addressing the effects of fluoxetine (among other SSRIs) exposure on non-target aquatic species. In 2003, one of the first studies addressed in detail the potential effects of fluoxetine on aquatic wildlife; this research concluded that exposure at environmental concentrations was of little risk to aquatic systems if a hazard quotient approach was applied to risk assessment. However, they also stated the need for further research addressing sub-lethal consequences of fluoxetine, specifically focusing on study species' sensitivity, behavioural responses, and endpoints modulated by the serotonin system. Fluoxetine – similar to several other SSRIs – induces reproductive behavior in some shellfish at concentrations as low as 10-10 M, or 30 parts per trillion. Since 2003, several studies have reported fluoxetine-induced impacts on many behavioural and physiological endpoints, inducing antipredator behaviour, reproduction, and foraging at or below field-detected concentrations. However, a 2014 review on the ecotoxicology of fluoxetine concluded that, at that time, a consensus on the ability of environmentally realistic dosages to affect the behaviour of wildlife could not be reached. At environmentally realistic concentrations, fluoxetine alters insect emergence timing. Richmond et al., 2019 find that at low concentrations it accelerates emergence of Diptera, while at unusually high concentrations it has no discernable effect.
==== Elon Musk ==== Former close ally Elon Musk, then-de facto head of the Department of Government Efficiency (DOGE), denounced the bill as a massive spending bill; he later called it a "disgusting abomination". Some Republican senators have come out in support of Musk's opinion. Republican opposition to the bill has been associated with the libertarian faction of the party. As Rand Paul backed Musk's criticism of the bill, others have criticized Paul's Senate Homeland Security and Governmental Affairs Committee proposals for requiring new federal employees to be required to pay a higher FERS contribution rate if they opt for Title 5 benefits while "at will" employees would pay a lower FERS contribution rate. The concern is that the increase in the number of at-will federal employees could allow the president to eliminate a large number of employees for any reason. The bill is credited with starting a public feud between Musk and Trump.
In response to the potential ban, many users signed up for the Chinese app Xiaohongshu (Chinese: 小红书), known internationally as REDnote. On 18 January 2025, hours before the bill went into effect, TikTok became unavailable across the country. The next day, TikTok restored access to their service after re-elected US President Donald Trump assured TikTok he would not enforce the law. President Trump signed an executive order on 20 January 2025, delaying the enforcement of the TikTok ban by 75 days. In April 2025, President Trump signed another executive order further delaying the enforcement of the TikTok ban by 75 days, and did so again in June 2025 with a 90-day extension. The Department of Justice's Office of Legal Counsel determined that TikTok USDS, the version of TikTok operated by the TikTok U.S. Data Security Joint Venture, was not subject to the No TikTok on Government Devices Act, thereby permitting employees to use TikTok on government devices, subject to agency discretion and workplace policies.
== Diagnosis == Affected patients may have normal, low, or slightly elevated TSH depending on the spectrum and phase of illness. Total T4 and T3 levels may be altered by binding protein abnormalities, and medications. Reverse T3 levels are generally increased, while FT3 is decreased. FT4 levels may have a transient increase, before becoming subnormal during severe illness. Correspondingly, in the majority of cases calculated sum activity of peripheral deiodinases (SPINA-GD) is reduced. Generally the levels of free T3 will be lowered, followed by the lowering of free T4 in more severe disease. Several studies described elevated concentrations of 3,5-T2, an active thyroid hormone, in NTIS. 3,5-T2 levels were also observed to correlate with concentrations of rT3 (reverse T3) in patients with euthyroid sick syndrome. NTIS is a component of a complex endocrine adaptation process, so affected patients might also have hyperprolactinemia and elevated levels of corticosteroids (especially cortisol) and growth hormone. NTIS can be difficult to distinguish from other forms of thyroid dysfunction in the hospital setting. Both NTIS and primary hypothyroidism may have reduced fT3 and fT4, and elevated TSH (which is common in the hospital, during the recovery phase of NTIS). Prescribing thyroxine to treat this may lead to lifelong thyroid overtreatment. Hyperthyroidism may be assumed due to decreased TSH and a transient fT4 increase. In some cases, this can be distinguished from NTIS by a thyroid ultrasound, which is commonly available in the hospital intensive care unit.
A study by Todd Harrison of the American Enterprise Institute estimated that the cost of developing and operating the Golden Dome until 2045 could range from $252 billion to $3.6 trillion, depending on how expansive the system is. Advocates of the Golden Dome describe a national missile defense shield as "a strategic imperative." In November 2025, United States Strategic Command nominee Richard Correll testified that the Golden Dome was key to ensure U.S. nuclear second strike capability. Critics suggest the costs for these capabilities have been underestimated, creating a "multi-trillion-dollar gap between rhetoric and reality." Article I of the Outer Space Treaty states that space is "the province of all mankind" and forbids placing weapons of mass destruction in orbit. Some permanent members of the United Nations Security Council have expressed objections to the Golden Dome program, citing inconsistencies with this principle. The program's use of space for attacking targets on the ground ("left of launch" preemptive strike capabilities) has led to discussion over the legality under international law. Some analysts argue the integration of such offensive payloads into low Earth orbit (LEO) introduces a severe economic and strategic instability driven by the harsh environmental constraints of the domain. LEO satellites function as "perishable munitions" due to rapid orbital decay, creating a “sunk cost trap” for high-value assets like the C-HGB, which has a procurement cost of approximately $41 million per unit according to the Congressional Budget Office.
Sources: en.wikipedia.org
Its sequence corresponds to the amino-terminal portion of prothymosin alpha, a larger protein present in many cell types. The isolated 28-residue peptide is a fragment of that protein rather than a separately encoded molecule, and laboratory material is produced by synthesis.
The single bridge between two cysteine residues holds the chain in a folded loop that influences its shape and its behavior in solution. Loss of the bridge through reduction or oxidation shifts chromatographic retention and is tracked during stability work.
It is a defined 28-residue sequence derived from a larger precursor, whereas many other thymic preparations are mixtures of several polypeptides. Its acetylated amino terminus and single disulfide bridge distinguish it chemically from unrelated thymic extracts.
It is a chain of 28 amino acids, with an acetyl group attached to the first serine residue. The synthetic version replicates this sequence. Its molecular mass is about 3,108 daltons.